Revelation Biosciences
REVB
9 hedge funds and large institutions have $39.3M invested in Revelation Biosciences in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$8.06M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$6.05M |
| 3 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$6.05M |
| 4 |
LA
Linden Advisors
New York
|
+$6.05M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$4.03M |
Top Sellers
REVB Hedge Fund Activity: Q4 2020 in Review
9 of the 5,675 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences (REVB) for Q4 2020, worth a combined $39.3M.
Buyers outnumbered sellers: 9 funds opened new REVB positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $8.06M.
- 9 institutional investors held Revelation Biosciences (REVB) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $39.3M of Revelation Biosciences stock for Q4 2020.
- 9 funds opened new Revelation Biosciences positions in Q4 2020 and 0 closed out, a net change of +9 holders.
- The largest Revelation Biosciences buyer in Q4 2020 was Boothbay Fund Management, an estimated $8.06M added.
Based on aggregated 13F filings for Q4 2020.